General

Lupin Neurosciences is committed to working with Healthcare Professionals to develop science-based solutions that stretch beyond access to lifechanging treatment options to optimize patient care in underserved neurological diseases.

Portfolio

Pipeline

Publications

2023 Congresses

General

Medical Inquiries & Adverse Event Reporting

Transparency Reporting

Late breaker: Post-authorization safety study (PASS). Mexiletine effectiveness in patients with non-dystrophic myotonia: interim analysis finding